Ask anything about research
Search papers, query evidence, get expert commentary — all in one place
ACC 2026 Late-Breaking Trials
Live trial results, expert commentary, and discussion with 10+ trial authors
Hot Research Today
Papers from every journal, all in one place
Evaluation and Management of the Child With Acute Decompensated Heart Failure: A Scientific Statement From the American Heart Association
This scientific statement highlights the need for guidance on managing acute decompensated heart failure in children, suggesting significant knowledge gaps.
“Published today, Evaluation and Management of the Child with Acute Decompensated Heart Failure: A Scientific Statement from the American Heart Association. A structured, rapid approach combining clinical assessment, diagnostics, and tailored therapy (medications, respiratory https://t.co/d684Q5aTc8”
Thanks to medical advances, we have more children living with heart disease and, therefore, more children coming into an emergency department or being hospitalized with heart failure. Research shows that once children get admitted for heart failure, they are much more likely than adults to need advanced cardiac therapies or die. And, while readmission rates have steadily declined in adults with heart failure — largely thanks to improved interventions and management practices — readmission rates have not changed for pediatric patients.
Post-Catheter Ablation Long-Term Antithrombotic Strategies in Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials
Does discontinuation of OAC after successful catheter ablation for atrial fibrillation safely prevent thromboembolic events compared to continued therapy?
Result: The incidence of thromboembolic events in patients who discontinued OAC after successful ablation remained low, though evaluation of net clinical benefit was limited by a low number of events.
Association Between Functional Status and Cardiac Function in Chronic Heart Failure: Insights from the C-MIC II Trial
Result: From baseline to 6 months, changes in KCCQ-OSS and 6MWD showed modest correlations with core lab-assessed LVEF (r=0.39; 95% CI: 0.16-0.58; p=0.0015 and r=0.39; 95% CI: 0.15-0.58; p=0.0022, respectively).
Surgical Care for Rheumatic Heart Disease Patients: Insights from the Netherlands Heart Registration
Does surgical mitral valve replacement in rheumatic heart disease patients yield similar one-year mortality compared to non-rheumatic heart disease patients and across different center volumes?
Result: One-year mortality did not differ significantly between RHD (6.4%) and non-RHD (13.8%) MVR patients (HR: 0.80; 95% CI 0.53-1.21; p=0.288).
Cardiovascular pharmacotherapy in year in 2025
Result: Summarizes 2025 advances in cardiovascular pharmacotherapy, including 4 new drug approvals (aficamten, etripamil, lerodalcibep, plozasiran), label expansions, major RCT results, and the withdrawal of Andexanet-alfa.
Sacubitril/Valsartan Versus Enalapril in Chagas Cardiomyopathy With Heart Failure: A Systematic Review and Meta-Analysis
Does sacubitril/valsartan reduce hospitalization for heart failure, cardiovascular mortality, or all-cause mortality compared to enalapril in patients with HFrEF due to Chagas cardiomyopathy?
Result: No statistically significant differences between sacubitril/valsartan and enalapril in hospitalization for heart failure (RR = 0.93; 95% CI, 0.74–1.16; P = 0.53), cardiovascular mortality (RR = 0.91; 95% CI, 0.73–1.12; P = 0.37), or all-cause mortality (RR = 0.96; 95% CI, 0.79–1.17; P = 0.69).
Tirzepatide versus Dulaglutide in Type 2 Diabetes Mellitus: Cardiovascular Insights from SURPASS-CVOT and Relevance to South Asian Populations
Does once-weekly tirzepatide reduce cardiovascular events compared to dulaglutide in patients aged ≥40 years with type 2 diabetes mellitus and established ASCVD?
Result: The primary composite endpoint occurred in 12.2% of patients treated with tirzepatide and 13.1% of those treated with dulaglutide (HR 0.92, 95.3% CI: 0.83–1.01), meeting non-inferiority (P = 0.003) but not superiority (P = 0.09).
Vertical Transmission of Type B Coxsackieviruses: A Systematic Review Emphasising Clinical Evidence and Seriousness of a Neglected Issue
What are the mechanisms and consequences of vertical transmission of Group B Coxsackieviruses from mother to infant?
Result: Vertical transmission of CV-B can occur through transplacental passage or inhalation during delivery, leading to serious consequences including abortion, stillbirth, congenital malformations, and neonatal morbidity and mortality.
“Vertical Transmission of Type B Coxsackieviruses: A Systematic Review Emphasising Clinical Evidence and Seriousness of a Neglected Issue #enteroviruses 👇 https://t.co/Si6R9cLjIg”
Epicardial-to-Endocardial Activation Gradients and Conduction Block During Atrial Fibrillation in the Human Left Atrial Posterior Wall
Result: Endocardial-epicardial LAPW asynchrony during persistent AF is characterized by greater epicardial compared with endocardial bipolar voltages, more frequent epicardial-to-endocardial activation gradients, and conduction block between surfaces.
Development of a Heart Failure Exacerbation Symptom Response System ― A Delphi Study ―
Result: Round 1 showed 50% of items with I-CVIs <0.78 (S-CVI/AVE=0.77), prompting revisions, and final I-CVIs exceeded 0.78 for >95% of items.
“We developed a system for early detection of heart failure exacerbation regardless of healthcare professional experience.Content validity was achieved I-CVI>0.78 for >95% of items. By Motohiro Sano @boso_chf_2023 https://t.co/fT7YlxLx1x #circ_rep #CardioX https://t.co/3S7siPWdVH”